New Gene Therapy Trial Targets Most Common Deafness Gene

A child just became the first person to receive an experimental gene therapy targeting the most common genetic cause of deafness, opening the door to potentially helping millions worldwide.

Skylark Bio announced Tuesday they've dosed their first patient with a therapy aimed at restoring hearing in children with GJB2 gene mutations. This genetic variation causes more cases of inherited deafness than any other known gene.

The timing couldn't be more promising. Just four months ago, the FDA approved Regeneron's Otarmeni, the first gene therapy that successfully restored hearing in children born deaf from a different genetic mutation. Some of those children heard their parents' voices for the first time, transforming indistinct murmurs into clear whispers.

That success proved gene therapy could work for inherited deafness. Now scientists are racing to tackle the bigger target.

The Ripple Effect

GJB2 mutations represent what researchers call the "holy grail" of hearing loss treatment. While the earlier therapy helped a small group with rare mutations, GJB2 affects far more people worldwide.

Startups across the United States, France, and China are now competing to develop solutions. Each team is working with slightly different approaches, but all share the same goal of restoring hearing through gene correction.

The earlier success with Otarmeni gave researchers crucial insights. "The ear stays completely intact in animal models, even into geriatric models," explained Joe Burns, former senior vice president of research at Decibel Therapeutics, which Regeneron acquired in 2023.

This structural preservation means the inner ear remains healthy enough to respond to genetic correction, even years after birth. That's critical because it suggests a wider treatment window than scientists initially expected.

The Skylark trial marks just the beginning. Researchers will carefully monitor this first patient and others who follow to ensure the therapy works safely and effectively.

For families living with inherited deafness, these developments represent genuine hope where little existed before.